Impax's NUMIENT granted EC marketing authorization for symptomatic treatment of adult patients with Parkinson's disease

November 25, 2015

Impax Laboratories, Inc. today announced that the European Commission has granted marketing authorization for NUMIENT (Levodopa and Carbidopa), a modified-release oral capsule formulation for the symptomatic treatment of adult patients with Parkinson's disease.

Previous Article
BioLight signs joint financing agreement with two Asia-based venture capital firms
BioLight signs joint financing agreement with two Asia-based venture capital firms

BioLight Life Sciences Investments, a company focused primarily on the discovery, development and commercia...

Next Article
WPI researchers awarded $1.3 million NIH grant to study use of copper to battle bacterial invader
WPI researchers awarded $1.3 million NIH grant to study use of copper to battle bacterial invader

Copper is an essential micronutrient that all organisms need to maintain healthy metabolism. But unless it ...